3-MeO-PCP
Common Names: Methoxyphencyclidine, MeO-PCP, MeO-PCP, PCP, MeO-PCE
Psychoactive Effects
Positive Effects
- Euphoria
Neutral Effects
- Dissociation
- Out-of-body experiences
- Visual distortions
- Altered time perception
- Reduced pain sensitivity
- Altered body perception
Negative Effects
- Depression
- Anxiety
Dosage Guidelines
| Route | Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|---|
| Oral | 2-5 mg | 5-15 mg | 15-25 mg | 25-40 mg | 40+ mg |
Duration
| Phase | Duration |
|---|---|
| Onset | 30-60 minutes |
| Peak | 2-4 hours |
| Total | 6-12 hours |
| After effects | 6-24 hours |
Pharmacology
Mechanism of Action: 3-MeO-PCP is a noncompetitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically binding to the phencyclidine (PCP) site.
Metabolism: Metabolized in the liver primarily by CYP3A4 and CYP2B6 enzymes.
Half-life: Approximately 4-6 hours, with effects typically lasting 6-12 hours.
Bioavailability: ~70% when taken orally, with peak plasma concentrations reached within 1-2 hours.
Risks and Harm Reduction
⚠️ Important: Always practice harm reduction. Start with low doses, test your substances, and ensure a safe set and setting. Never use alone.
Legal Status
Disclaimer: Legal status varies by jurisdiction and may change. This information is for educational purposes only.
References
- • Zanos, P., et al. (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 533(7604), 481-486.
- • Morgan, C. J., et al. (2012). Ketamine use: a review. Addiction, 107(1), 27-38.
- • Information compiled from PsychonautWiki